Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 9/20 | 0.77 |
| ▸ | DRD2 | P14416 | 3/20 | 0.54 |
| ▸ | DRD4 | P21917 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23746709 | 0.92 | GRM2 (0.69) | GRM2DRD2DRD4 | |
| SCHEMBL23719415 | 0.91 | GRM2 (0.67) | GRM2DRD2DRD4 | |
| SCHEMBL23746708 | 0.88 | GRM2 (0.74) | GRM2DRD2DRD4 | |
| SCHEMBL23719406 | 0.87 | GRM2 (1.00) | GRM2DRD2DRD4 | |
| SCHEMBL23719444 | 0.87 | GRM2 (0.67) | GRM2DRD2DRD4 | |
| SCHEMBL4725327 | 0.86 | GRM2 (0.73) | GRM2DRD2DRD4 | |
| Hydrochloric Acid SCHEMBL4777820 | 0.85 | GRM2 (0.72) | GRM2DRD2DRD4 | |
| SCHEMBL4941734 | 0.79 | GRM2 (0.69) | GRM2DRD2DRD4 | |
| SCHEMBL23719511 | 0.79 | GRM2 (0.63) | GRM2 | |
| SCHEMBL23719509 | 0.79 | GRM2 (0.63) | GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210246140-A1 | MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-08-12 | — | — | US | disclosed |
| WO-2021155196-A1 | MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 | THE GENERAL HOSPITAL CORPORATION (US) | 2021-08-05 | — | — | WO | disclosed |
| US-20080312271-A1 | AZABENZIMIDAZOLYL COMPOUNDS | PFIZER INC. | 2008-12-18 | — | — | US | disclosed |
| WO-2008012622-A2 | AZABENZIMIDAZOLYL COMPOUNDS AS POTENTIATORS OF MGLUR2 SUBTYPE OF GLUTAMATE RECEPTOR | PFIZER PRODUCTS INC. (US) | 2008-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210246140-A1 | MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 | GRM1, GRM2, GRIN1 | GRM2 2/4885DRD2 430/4885DRD4 889/4885 |
| US-20080312271-A1 | AZABENZIMIDAZOLYL COMPOUNDS | AZI2, PAICS, UGT2B7 | GRM2 4077/4885DRD2 1974/4885DRD4 1020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.